Elevation Oncology, Inc.
Elevation Oncology, Inc. (ELEV) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
elev · stock forecast · 12 analysts (3M) · FMP · updated Nov 5, 2025
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Hold
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$10.00
Consensus
$9.00
+2365.8% upside
Low
$8.00
Median: $9 · Last Close: $0.36
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ELEV · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-06-10 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2025-06-10 | JMP Securities | Maintains | Market Perform→Market Perform |
| 2025-06-09 | William Blair | Downgrade ↓ | Outperform→Market Perform |
| 2025-03-24 | Stephens & Co. | Downgrade ↓ | Overweight→Equal Weight |
| 2025-03-21 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2025-03-21 | Leerink Partners | Downgrade ↓ | Outperform→Market Perform |
| 2025-03-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-21 | JMP Securities | Downgrade ↓ | Market Outperform→Market Perform |
| 2025-03-21 | Citizens Capital Markets | Downgrade ↓ | Market Outperform→Market Perform |
| 2025-03-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Elevation Oncology, Inc. (ELEV) stock. Of the recent 38 rating actions, 1 were upgrades and 10 were downgrades. 12 analysts currently cover ELEV.
Analyst Recommendation Trends
ELEV analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$0M
EPS This Year
$-0.71
EPS Next Year
$-0.51
↓ 28.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast ELEV EPS of $-0.71 for the current fiscal year, based on estimates from 4 analysts. The ELEV revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ELEV stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ELEV price target is $9.00 (+2365.8% upside), with an analyst consensus of Hold.
Elevation Oncology, Inc. trades on NASDAQ under the ticker ELEV. The ELEV stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 25% of covering analysts.
Frequently asked questions
ELEV forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month ELEV price target is $9.00, with a high forecast of $10.00 and a low of $8.00. The median price target is shown in the chart above when available. This implies +2365.8% potential upside from the current price of $0.36.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.